Kiniksa Pharmaceuticals Market Sentiment

Kiniksa Pharmaceuticals International PLC

KNSANASDAQ

$91.81

-0.43-0.47%

Últ. Act.: Nov 2, 3:07 PM

Panorámica general Noticias Previsión de beneficios Eventos Precios objetivo FinanzasSentimientoPropiedad Comparar Opciones Informe de acciones

Ganancias: Los beneficios de Q3 2026 se publicaron el mar oct 27th, antes de la apertura del mercado

Conferencia telefónica: La conferencia telefónica más reciente comenzó a las 8:30 a. m., hace 6 días

Haz clic para ver el webcast

Kiniksa Pharmaceuticals Market Sentiment - Benzinga

Kiniksa Pharmaceuticals Market Sentiment

Market sentiment signals for Kiniksa Pharmaceuticals (KNSA): analyst consensus, short interest, options flow and insider activity.

Key Signals

Analyst Consensus▲ Buy

Short Interest▲ 9.3% short float

Options Flow▲ 0.05 P/C ratio

Insider Activity— N/A

Analyst Consensus

Buy

10 analysts

Options Flow (P/C)

0.05

More calls — Bullish

1,000 calls · 52 puts

Avg Consensus PT

$87

-4.9%

Highest Price Target

$122

+32.9%

JP Morgan

Lowest Price Target

$35

-61.9%

Evercore ISI Group

Short Interest

9.3%

Declining — Bullish

Insider Activity (30d)

—

Short Interest — % of Float

Recent Analyst Actions

Date	Firm	Analyst & Accuracy	Upside / Downside	PT Change	Action	Rating
Oct 30, 2026	JP Morgan	Anupam Rama—	+32.9%	$107 → $122	Maintained	Overweight
Oct 28, 2026	Goldman Sachs	Paul Choi—	+10.0%	$90 → $101	Maintained	Buy
Oct 28, 2026	Wedbush	David Nierengarten—	+11.1%	$99 → $102	Maintained	Outperform
Oct 28, 2026	Wells Fargo	Yanan Zhu—	+19.8%	$87 → $110	Maintained	Overweight
Jul 30, 2026	Goldman Sachs	Paul Choi—	-2.0%	$75 → $90	Maintained	Buy
Jul 29, 2026	JP Morgan	Anupam Rama—	+16.5%	$72 → $107	Maintained	Overweight
Jul 29, 2026	Canaccord Genuity	Edward Nash—	+6.7%	$64 → $98	Maintained	Buy
Jul 29, 2026	Wedbush	David Nierengarten—	+7.8%	$72 → $99	Maintained	Outperform
Jul 29, 2026	Citigroup	Geoff Meacham—	+8.9%	$60 → $100	Maintained	Buy
Jul 23, 2026	Goldman Sachs	Paul Choi—	-18.3%	$60 → $75	Maintained	Buy
Jul 13, 2026	Wells Fargo	Eva Fortea Verdejo—	-19.4%	$57 → $74	Maintained	Overweight
Jun 29, 2026	Wedbush	David Nierengarten—	-21.6%	$59 → $72	Maintained	Outperform
Apr 29, 2026	Canaccord Genuity	Edward Nash—	-30.3%	$62 → $64	Maintained	Buy
Apr 29, 2026	Citigroup	Geoff Meacham—	-34.6%	$50 → $60	Maintained	Buy
Apr 29, 2026	Wedbush	David Nierengarten—	-35.7%	$58 → $59	Maintained	Outperform
Apr 29, 2026	Wells Fargo	Eva Fortea Verdejo—	-37.9%	$53 → $57	Maintained	Overweight
Apr 28, 2026	Jefferies	Roger Song—	-22.7%	$58 → $71	Maintained	Buy
Apr 16, 2026	Wedbush	David Nierengarten—	-36.8%	$53 → $58	Maintained	Outperform
Feb 25, 2026	Wells Fargo	Eva Fortea Verdejo—	-42.3%	$50 → $53	Maintained	Overweight
Feb 25, 2026	Wedbush	David Nierengarten—	-42.3%	$50 → $53	Maintained	Outperform
Feb 19, 2026	Canaccord Genuity	Edward Nash—	-32.5%	$62	Initiate	Buy
Jan 13, 2026	Wedbush	David Nierengarten—	-45.5%	$48 → $50	Maintained	Outperform
Oct 29, 2025	Goldman Sachs	Paul Choi—	-40.1%	$45 → $55	Maintained	Buy
Oct 17, 2025	Citigroup	Geoff Meacham—	-45.5%	$45 → $50	Maintained	Buy
Oct 13, 2025	Wedbush	David Nierengarten—	-52.1%	$38 → $44	Maintained	Outperform